Summary

for people ages 18-55 (full criteria)
at San Diego, California and other locations
study started
estimated completion:

Description

Summary

The purpose of this trial is to test if VC-01™ combination product can be implanted subcutaneously in subjects with Type 1 Diabetes and maintained safely for two years. It will also test if VC-01 is an effective treatment for subjects with Type 1 Diabetes.

Official Title

A Prospective, Multicenter, Open-Label, First-in-Human Phase 1/2 Study With Two Cohorts to Evaluate the Safety, Tolerability, and Efficacy of Various Doses of VC-01™ Combination Product in Subjects With Type 1 Diabetes Mellitus

Keywords

Type 1 Diabetes Mellitus Diabetes Mellitus Diabetes Mellitus, Type 1 VC-01™ Combination Product

Eligibility

You can join if…

Open to people ages 18-55

  • Men and women (non-pregnant and non-childbearing potential)
  • Diagnosis of type 1 diabetes mellitus for at least 3 years
  • Stable diabetic treatment
  • Willingness to use a continuous glucose meter
  • Acceptable candidate for implantation

You CAN'T join if...

  • Advanced complications associated with diabetes
  • Immunosuppressive therapy

Locations

  • University of California at San Diego
    San Diego California United States
  • University of Alberta Hospital
    Edmonton Alberta T6G 2B7 Canada

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
ViaCyte
ID
NCT02239354
Phase
Phase 1/2
Study Type
Interventional
Last Updated
May 2017